BGB-A317

Ligand id: 9592

Name: BGB-A317

Classification
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Synonyms
hu317-1/IgG4mt2 | tislelizumab (proposed INN)
Comments
BGB-A317 is a humanized IgG4 monoclonal antibody targeting the PD-1 immune checkpoint. BGB-A317 acts to prevent the binding of the ligands PD-L1 and PD-L2 to PD-1. It is an immuno-oncology drug candidate being developed by Beigene Ltd (see their patent US8735553B1 [2]).
Database Links
GtoPdb PubChem SID 340590223